Hengrui Pharma and Kailera Therapeutics Announce Additional Data from Phase 3 Obesity Trial in China of Dual GLP-1/GIP Receptor Agonist HRS9531
– Mean weight loss of 19.2%I at 6 mg with no plateau and favorable safety profile in 48-week Phase 3 clinical trial – – Data builds on previously reported Phase 2 results that showed mean weight loss of 23.6%I at 8 mg at week 36 with no plateau – – NDA submitted in China by […]